Epigenetic research reveals a potential treatment for CRC and other solid tumors

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

Researchers at the University of Chicago Medicine Comprehensive Cancer Center have discovered that high doses of radiation cause growth in existing metastatic tumors that weren’t directly treated with radiation.

May 16, 2025

Vol.51 No.19

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

April 11, 2025

Vol.51 No.14

Clinical Roundup

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.

April 04, 2025

Vol.51 No.13

In Brief

Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

Elana J. Fertig was named associate director for quantitative science at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

March 21, 2025

Vol.51 No.11

In Brief

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.

March 21, 2025

Vol.51 No.11

Epigenetic research reveals a potential treatment for CRC and other solid tumors

YOU MAY BE INTERESTED IN

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Renew today!

Subscriber content

Never miss an issue!

Login